Product Description
an inhaled small-molecule pan-selectin antagonist (Sourced from: https://pubmed.ncbi.nlm.nih.gov/16140027/)
Mechanisms of Action: P-selectin Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Revotar
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Psoriasis|Chronic Obstructive Pulmonary Disease|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2006-7041-83/hah | N/A |
Not yet recruiting |
Stress Disorders, Post-Traumatic |
2020-06-29 |
|
| 2009-017257-35 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2010-12-17 |
|
| 2009-013163-18 | P2 |
Completed |
Healthy Volunteers |
2009-12-17 |
|
| Psoriasis POC | P2 |
Completed |
Psoriasis |
2009-08-20 |